CTRI/2010/091/000432招募中未知
Clinical study on the use of ex vivo expanded allogeneic mesenchymal stem cells for Parkinson's disease
ADVANCED NEURO-SCIENCE ALLIES PVT. LTD#560, Bhargavi, 9th "A" Main, Indiranagar, Bangalore-560 038Karnataka (INDIA)0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion of patients for therapy will be under the investigator's discretion. However the following criteria will be considered.
- •1. Should be in the age group of 18-80 years.
- •2. Should be fully conscious, alert and oriented while providing consent
- •3. Should show significant motor and non motor symptoms
- •4. Subject should understand the requirements of study
- •5. Subject should provide a written informed consent and agree to return for Follow up
- •6. Subject should be clinically diagnosed for Parkinson's disease with motor complications despite adequate oral anti-parkisonian therapy.
- •7. Should be able to comply with and understand the required visit schedule and complete the same.
排除标准
- •Exclusion of patients from therapy will be under the investigator's discretion. However the following criteria will be considered
- •1. Patient is suffering from Dementia (MMSE <25)
- •2. Patient is suffering from a neurodegenerative disorder other than Parkinson.
- •3. The extent or severity of the disease is not measurable.
- •4. If the subject suffers from pre-existing medical conditions such as bleeding disorders, septicemia.
- •5. Patients with a past (within one year) or present history of psychiatric disorder.
- •6. If the subject has been enrolled in other investigational drug trial or has completed any trial within the last 3 months.
- •7. If Hemoglobin < 10gm/dl, Serum Creatinine< 2mg/dl serum total bilirubin< 2mg /dl and HbA1c<7?
- •8. Pregnant or nursing or women in child bearing age without adequate contraception.
- •9. The subject tested positive for HIV, HCV, HBV,or VDRL
研究者
相似试验
招募中
不适用
Clinical study on the use of ex vivo expanded Allogenic Mesenchymal Stem Cells for Cerebral PalsyCTRI/2010/091/000435ADVANCED NEURO-SCIENCE ALLIES PVT. LTD#560, Bhargavi, 9th "A' Main, Indiranagar, Bangalore-560 038Karnataka (INDIA)15
已完成
1 期
Immune cell therapy for patients with COVID-19 related pneumonia using allogenic ex vivo NK cellsIRCT20200621047859N2Motamed Cancer Institute15
招募中
1 期
A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphomarelapsed/refractory CD20 positive B-cell lymphomaJPRN-UMIN000014072Department of Hematology, Tokyo Women's Medical University10
尚未招募
1 期
atural Killer imune cells expansion for Acute Myeloid Leukemia treatment.Acute myeloid leukaemia Myelodysplastic syndrome, unspecifiedD46.9C92.0RBR-8qq5h9Hospital Israelita Albert Einstein
已完成
不适用
Study of effectiveness of a day cream product in combination with a night cream in reducing dark spots in asian adult females over a period of 3 monthsCTRI/2012/02/002420Oriflame Research and Development Ltd36